期刊文献+

MiRNA-199a-3p通过mTOR通路与阿霉素联合抑制子宫内膜癌细胞的增殖和促凋亡作用 被引量:6

MiRNA-199a-3p combined with doxorubin inhibits endometrial cancer cell proliferation and promotes apoptosis through the mTOR pathway
下载PDF
导出
摘要 目的:探讨阿霉素对转染miRNA-199a-3p的子宫内膜癌(EC)的作用及机制。方法:构建pSIREN-miRNA-199a-3p过表达质粒并稳定转染内膜癌细胞系Ishikawa、SPEC-2细胞。应用逆转录PCR(RT-PCR)检测miRNA-199a-3p的表达;MTT、克隆形成实验检测细胞增殖;流式细胞术检测细胞凋亡;Western blot检测mTOR信号通路相关蛋白表达。结果:上调miRNA-199a-3p可显著抑制子宫内膜癌细胞Ishikawa、SPEC-2的克隆形成能力(P<0.01,P<0.05);miRNA-199a-3p可增强阿霉素对Ishikawa、SPEC-2细胞的生长抑制(P均<0.05)和凋亡诱导作用(P均<0.05);Western blot证实,miRNA-199a-3p可显著下调mTOR及其效应蛋白p70S6K的磷酸化水平。结论:miRNA-199a-3p可能通过mTOR通路与阿霉素联合抑制子宫内膜癌细胞的增殖并促进其凋亡,为联合应用miRNA和阿霉素治疗EC提供了实验依据。 Objective:To study the effect and mechanism of doxorubicin on miRNA- 199a-3p transfected endometrial carcinoma (EC). Methods: The pSIREN-miRNA-199a-3p overexpression plasmids were stably tranfected into Ishikawa and SPEC-2 cells. RT-PCR was used to confirm the upregulation of miRNA-199a-3p. Cellular proliferation was determined by the MTT assay and colony formation assay. The apoptotic status was detected by flow cytometr. The alterations of proteins in the mTOR pathways were measured by Western blot. Results:Up- regulation of miRNA-199a-3p significantly suppressed the colon forming in Ishikawa and SPEC- 2 cells(P〈0.01 ,P〈0.05),and miRNA-199a-3p sensitized these two cells to doxorubicin(P〈 0.05,P〈0.05). Moreover, miRNA-199a-3p promoted the effects of doxorubicin on cellular ap- optosis(P〈0.05, P〈0.05). Western blot showed that miRNA-199a-3p further enhanced the mTOR signal inhibition of doxorubicin. Conclusions: MiRNA-199a-3p may be combined with doxorubicin to inhibit proliferation of EC cells and promote the apoptosis through mTOR path- way. This study will provide experimental basis for the combination of miRNA and doxornbicin in the treatment of EC.
出处 《现代妇产科进展》 CSCD 2014年第9期673-676,共4页 Progress in Obstetrics and Gynecology
关键词 子宫内膜癌 miRNA-199a-3p MTOR 增殖 凋亡 Endometrial cancer miRNA-199a-3p m-TOR signal pathway Proliferation Apoptosis
  • 相关文献

参考文献15

  • 1Hasumi K,Sugiyama Y, Sakamoto K, et al. Small endometrial carcinoma 10mm or less in diameter: clinicopathologic and histogenetic study of 131 cases for early detection and treat- ment[ J]. Cancer Med ,2013,2(6) :872-880.
  • 2杨淑丽,苗劲蔚.人附睾蛋白4在子宫内膜癌诊断中的应用[J].中国医刊,2013,48(11):25-27. 被引量:3
  • 3Li Z,Min W,Gou J. Knockdown of eyelophilin A reverses pa- clitaxel resistance in human endometrial cancer cells via sup- pression of MAPK kinase pathways [ J ]. Cancer Chemother Pharmacol,2013,72(5) :1001-1011.
  • 4Takwi AA,Wang YM,Wu J,et al. MiR-137 regulates the con- stitutive and rostane receptor and modulates doxorubicin sen- sitivity in parental and doxorubicin-resistant neuroblastoma cells [ J ]. Oncogene,2013 [ Epub ahead of print ].
  • 5Cheng W,Liu T,Wan X,et al. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multi drug resistance of o- varian cancer-initiating cells [J]. FEBS J,2012,279 ( 11 ) : 2047-2059.
  • 6Fabbri M. TLRs as miRNA receptors [J]. Cancer Res,2012, 72(24) :6333-6337.
  • 7Ambros V. MicroRNA pathways in flies and worms:growth, death,fat,stress ,and timing[ J ]. Cell ,2003,113(6) :673-676.
  • 8Shatseva T, Lee DY, Deng Z, et al. MicroRNA miR-199a-3p regulates cell proliferation and strrvival by targeting caveolin- 2[J]. J Cell Sei,2011,124(m16) :2826-2836.
  • 9沈晓燕,向阳.子宫内膜癌化疗进展[J].国际妇产科学杂志,2010,37(6):436-439. 被引量:7
  • 10Ren Y,Zhou X, Mei M,et al. MicroRNA-21 inhibitor sensiti- zes human gIioblastoma cells U251 (PTEN-mutant) and LN229 (l~I'EN-wild type) to taxol [ J ]. BMC Cancer, 2010, 10:27.

二级参考文献38

  • 1Maggi R,Lisseni A,Spins F,et al.Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma:results of a randomised trial[J].Br J Cancer,2006,95(3):266-271.
  • 2Hogberg T.A randomized phase-Ⅲ study on adjuvant treatment with radiation (RT)(+/-)chemotherapy (CT) in early-stage highrisk endometrial cancer (NSGO-EC-9501/EORTC 55991)[J].J Clin Oncol(Meeting Abstracts),2007,25(18 Suppl):5503.
  • 3Humber CE,Tiemey JF,Symonds RP,et al.Chemotherapy for advanced,recurrent or metastatic endometrial cancer:a systematic review of Coehrane collaboration[J].Ann Oncol,2007,18(3):409-420.
  • 4Thigpen JT,Brady MF,Homesley HD,et al.Phase Ⅲ trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma:a gynecologic ontology group study[J].J Clin Oncol,2004,22(19):3902-3908.
  • 5Fleming GF.Systemic chemotherapy for uterine carcinoma:metastatic and adjuvant[J].J Clin Oncol,2007,25(20):2983-2990.
  • 6Dizon DS,Blessing JA,McMeekin DS,et al.Phase Ⅱ trial of ixahepilone as second-line treatment in advanced endometrial cancer:gynecologic oncology group trial 129-P[J].J Clin Oncol,2009,27(19):3104-3108.
  • 7Secord AA,Havrilesky LJ,O'Malley DM,et al.Amulticenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer[J].Gynecol Oncol,2009,114(3):442-447.
  • 8Lupe K,D'Souza DP,Kwon JS,et al.Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer[J].Gynecol Oncol,2009,114(1):94-98.
  • 9Fleming GF,Brunetto VL,Cella D,et al.Phase Ⅲ trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma:a Gynecologic Oncology Group Study[J].J Clin Oncol,2004,22(11):2159-2166.
  • 10McMeekin DS,Filiaci VL,Thigpen JT,et al.The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials:a Gynecologic Oncology Group study[J].Gynecol Oncol,2007,106(1):16-22.

共引文献8

同被引文献22

引证文献6

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部